Observation on clinical efficacy of dapagliflozin combined with β-blockers in the treatment of heart failure(EF<40%)complicated with ventricular arrhythmias
Observation on clinical efficacy of dapagliflozin combined with β-blockers in the treatment of heart failure(EF<40%)complicated with ventricular arrhythmias
Objective To discuss the clinical effect of dagliflozin combined with β-blockers in heart failure with ventricular arrhythmia with ejection fraction(EF)<40%.Methods 60 patients with heart failure(EF<40%)and ventricular arrhythmias were selected as randomly subjects and randomly divided into a control group and an experimental group,each consisting of 30 patients.The control group was treated with β-blockers,and the experimental group was treated with dapagliflozin+β-blockers.The therapeutic effect,the number of ventricular premature beat,the number of nonsustained ventricular tachycardia,the occurrence of adverse reactions and re-hospitalization were compared between the two groups.Results The total effective rate of the control group was 66.67%,which was significantly lower than 96.67%of the experimental group(P<0.05).After treatment,the number of ventricular premature beat and nonsustained ventricular tachycardia in both groups were lower than that before treatment(P<0.05).After treatment,the number of ventricular premature beat and nonsustained ventricular tachycardia were(1877.66±272.23)and(2.30±1.66)time/24 h in the experimental group,which were lower than(2153.60±352.71)and(3.78±1.57)time/24 h in the control group(P<0.05).The incidence of adverse reactions of 6.67%in the experimental group was lower than 26.67%in the control group(P<0.05).The re-hospialization rate of 10.00%in the experimental group was lower than 33.33%in the control group(P<0.05).Conclusion Dapagliflozin combined with β-blockers shows good effect on patients with heart failure(EF<40%)and ventricular arrhythmias.
维普
万方数据